ImmunityBio (IBRX) Non-Current Assets (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Non-Current Assets of $193.7 million for Q1 2026, little changed year-over-year from $194.6 million in Q1 2025, and up 3.56% quarter-over-quarter from $187.0 million in Q4 2025.
ImmunityBio (IBRX) Non-Current Assets (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Non-Current Assets for 13 consecutive years, with $193.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets changed 0.47% year-over-year to $193.7 million; the TTM figure through Mar 2026 stood at $764.1 million (down 3.99% YoY), while the FY2025 annual figure was $187.0 million, down 5.71% from the prior year.
- Non-Current Assets rose to $193.7 million in Q1 2026 per IBRX's latest filing, from $187.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $229.9 million in Q1 2023 and bottomed at $177.2 million in Q1 2022.
- Historically, Non-Current Assets has averaged $203.4 million across 5 years, with a median of $201.5 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 74.92% — and 2024, when it slipped 10.85%.
- ImmunityBio's Non-Current Assets stood at $221.8 million in 2022, then slipped by 5.15% to $210.4 million in 2023, then declined by 5.71% to $198.3 million in 2024, then declined by 5.71% to $187.0 million in 2025, then climbed by 3.56% to $193.7 million in 2026.
- Business Quant data shows IBRX's Non-Current Assets at $193.7 million in Q1 2026, $187.0 million in Q4 2025, and $189.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 189.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 189.52 Mn |
| Mar 31, 2026 | 193.68 Mn |
| Dec 31, 2025 | 187.02 Mn |
| Sep 30, 2025 | 189.49 Mn |
| Jun 30, 2025 | 193.94 Mn |
| Mar 31, 2025 | 194.60 Mn |
| Dec 31, 2024 | 198.35 Mn |
| Sep 30, 2024 | 201.42 Mn |
| Jun 30, 2024 | 201.50 Mn |
| Mar 31, 2024 | 204.96 Mn |
| Dec 31, 2023 | 210.37 Mn |
| Sep 30, 2023 | 217.34 Mn |
| Jun 30, 2023 | 224.40 Mn |
| Mar 31, 2023 | 229.91 Mn |
| Dec 31, 2022 | 221.78 Mn |
| Sep 30, 2022 | 209.85 Mn |
| Jun 30, 2022 | 202.73 Mn |
| Mar 31, 2022 | 177.25 Mn |
| Dec 31, 2021 | 134.56 Mn |
| Sep 30, 2021 | 119.97 Mn |